The rising prevalence of arthritis coupled with large number of clinical trials is impelling the growth of the market
Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
Several companies are undergoing extensive clinical trials and R&D activities, which in turn, is expected to augment a major growth factor for global adalimumab market. The reimbursement coverage and well-defined regulatory guidelines are further expected to fuel the market growth through 2028. However, patent expiration of blockbuster drugs is expected to slow down the market growth. Besides, side effects associated with the drugs is expected to restrain the growth of the market.
Global adalimumab market is segmented based on based on type, product type, therapeutic area, distribution channel, end user, company and region. Based on therapeutic area, the market is categorized into rheumatoid arthritis, psoriatic arthritis, psoriasis, Crohn’s disease, and others. Among them, the rheumatoid arthritis is expected to dominate the global market owing to high prevalence among elderly population.
Regionally, North America is expected to dominate the global adalimumab market followed by Europe. The advanced healthcare infrastructure and well-organized regulatory framework in these two regions is making them a lucrative market for adalimumab manufacturers.
Major companies operating in global adalimumab market include Abbvie Inc., Pfizer Inc., Amgen Inc., Novartis AG, Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd, Boehringer Ingelheim International GmbH, Mylan N.V., Hetero Biopharma Ltd., and Samsung Bioepis Co Ltd. The market players are undergoing extensive clinical trials to test the safety and efficacy of the adalimumab in treatment of various diseases.
Objective of the Study:
To analyse and forecast the market size of global adalimumab market.To forecast global adalimumab market based on based on type, product type, therapeutic area, distribution channel, end user, company and region.
To identify drivers and challenges for global adalimumab market.
To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in global adalimumab market.
To identify and analyse the profile of leading players operating in the global adalimumab market.
The publisher performed both primary as well as exhaustive secondary research for this study. Initially, The research team sourced a list of adalimumab manufacturing companies across the globe. Subsequently, The research team conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, the publisher could include the companies which could not be identified due to the limitations of secondary research.
The publisher calculated global adalimumab market size using a bottom-up approach, where data for various end user industries and its application across various product types were recorded and forecast for the future years. The research team sourced these values from the industry experts and company representatives and externally validated through analysing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used.
Key Target Audience:
- Adalimumab manufacturers, companies, partners, hospitals pharmacy/retail pharmacy and other stakeholders
- Government bodies such as regulating authorities and policy makers
- Organizations, industry associations, forums and alliances related to adalimumab
Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as adalimumab manufacturing companies, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.Report Scope:
In this report, global adalimumab market has been segmented into following categories, in addition to the industry trends which have also been detailed below:Global Adalimumab Market, By Type:
- Biologics
- Biosimilar
Global Adalimumab Market, By Product Type:
- Branded
- Generics
Global Adalimumab Market, By Therapeutic Area:
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Psoriasis
- Crohn’s Disease
- Others
Global Adalimumab Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Global Adalimumab Market, By End User:
- Hospitals & Clinics
- Home Healthcare
- Others
Global Adalimumab Market, By Region:
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- North America
- United States
- Mexico
- Canada
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in global adalimumab market.Available Customizations:
With the given market data, the publisher offers customizations according to a company’s specific needs. The following customization options are available for the report:Company Information
Detailed analysis and profiling of additional market players (up to five).Profit Margin Analysis
Profit margin analysis in case of direct and indirect sales channel.This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbvie Inc.
- Pfizer, Inc.
- Amgen Inc.
- Novartis AG
- Torrent Pharmaceuticals Ltd.
- Cadila Healthcare Limited
- Boehringer Ingelheim International GmbH
- Mylan N.V.
- Hetero Biopharma Ltd
- Samsung Bioepis Co Ltd.